Journal article icon

Journal article

Randomized noninferiority trial of dihydroartemisinin-piperaquine compared with sulfadoxine-pyrimethamine plus amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso

Abstract:

The WHO recommends that children living in areas of highly seasonal malaria transmission in the Sahel subregion should receive seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine plus amodiaquine (SPAQ). We evaluated the use of dihydroartemisinin-piperaquine (DHAPQ) as an alternative drug that could be used if SPAQ starts to lose efficacy. A total of 1,499 children 3 to 59 months old were randomized to receive SMC with SPAQ or DHAPQ over 3 months. The primary outcome measure...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1128/aac.04923-14

Authors


More from this funder
Name:
Holley Cotec Pharmaceutical Company Ltd
Publisher:
American Society for Microbiology
Journal:
Antimicrobial agents and chemotherapy More from this journal
Volume:
59
Issue:
8
Pages:
4387-4396
Publication date:
2015-07-16
Acceptance date:
2015-04-16
DOI:
EISSN:
1098-6596
ISSN:
0066-4804
Language:
English
Pubs id:
pubs:522523
UUID:
uuid:61e6bd72-3981-4fe0-bd64-7a90b24e83aa
Local pid:
pubs:522523
Source identifiers:
522523
Deposit date:
2016-04-01

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP